Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Intuitive’s trade war strategy holds lessons for other device developers

April 22, 2025 By Jim Hammerand

A photo of an Intuitive Surgical endoscope assembler at work in one of the device developer's European manufacturing facilities.

An Intuitive Surgical endoscope assembler at work in one of the device developer’s European manufacturing facilities. [Photo courtesy of Intuitive Surgical]

Intuitive Surgical’s approach to the global trade war set off by President Donald Trump’s import taxes could help other device developers and manufacturers navigate tariff turmoil.

In 2024, Intuitive manufactured 98% of its robotic systems in the U.S., 70% of its endoscopes in Europe, and about 80% of its instruments and accessories in Mexico, CFO Jamie Samath said while discussing the company’s financial and operating results for the first quarter of 2025.

“We source raw materials and other components that go into these finished products from suppliers around the world,” he said. “The net result of our manufacturing footprint and global customer demand is that Intuitive is both a significant U.S. manufacturer and has become a significant net U.S. exporter.”

On the same call, Intuitive CEO Gary Guthart described the surgical robotics leader’s “principles for navigating the current environment.”

A portrait of Intuitive Surgical CEO Gary Guthart.

Intuitive Surgical CEO Gary Guthart [Photo courtesy of Intuitive Surgical]

“Our first priority is to assure supply of our products to our customers globally,” he said. “We have spent years becoming a trusted provider of great products and services, and our first commitment is to maintaining the status for those who depend upon us. We believe that high-quality, minimally invasive care at industrial scale will remain a global need, regardless of trade policy. And our long-term opportunity remains robust. We will continue to manage the business for the long-term and invest toward improvement in the Quintuple Aim.”

(If you’re not familiar with the Quintuple Aim, Guthart has defined it in recent years as the mission “to deliver better patient outcomes and improved patient and care team experiences, while lowering treatment costs, reducing the duration of hospital admissions, and enabling access to care.”)

Register now: The MDO Min-Vasive Medtech Series returns in August 2025

Guthart said price hikes aren’t on the table just yet.

“Given potential changes in our costs and our customers’ costs across their enterprise, we do not plan reflexive changes to our pricing in that dynamic, near-term environment,” he said. “Our second priority will be to optimize our production costs and rebalance product flows within our existing manufacturing and supply chain footprint as policies begin to stabilize. Finally, we will adjust our supply chain strategy and assess adjustments to our pricing when we see the signs of a durable planning environment for trade.”

Intuitive is assuming that retaliatory tariffs will go into effect after Trump’s 90-day pause lapses.

“We’ll see how that plays out,” Samath said. “…With respect to the manufacturing operations in our supply chain, to the extent that there are low-hanging fruit that isn’t disruptive to our partners and our employees, then of course we’ll pursue those. But I think our first move is to let things stabilize and evaluate then what’s possible. We’ll do that concurrently across the year, and we will consider things like: Do you have to invest to mitigate? What’s the time to receive the benefit? What’s the economic return of that?”

“There are complexities in some of the things that you might do from an operational perspective,” he continued, “so we don’t want to move too quickly, given how dynamic the environment is.”

Supply chain risk mitigation is ongoing

A portrait of Intuitive President Dave Rosa.

Intuitive President Dave Rosa [Photo courtesy of Intuitive]

Intuitive President Dave Rosa said the device manufacturer’s supply chain team can apply many of its core strategies to deal with new import taxes.

“It’s really two frames of reference that you ought to use. One is thinking about the parts that are coming into our factories, the ones that we assemble. And then the other frame of reference are the parts that are leaving our factories,” he said. “… Our teams have been working to get to industrial scale for four years now, and so some of the processes that exist within this framework inside of Intuitive really center around assessing risk in all of our supply chain. We procure thousands of parts for our systems and and instruments. And so our teams look through there, assess the risk and then ensure appropriate mitigations are in place. [It’s] a robust process that runs on a daily basis.”

Those mitigations can include dual sourcing and building strategic reserves, Rosa said.

“If you look at our parts, our components and our products going to customers, we’ve done a lot of work to qualify some of our products under USMCA. We’ve optimized inventory around the globe ahead of some of these tariffs taking place,” he said. “And then if you look in the mid-term, we can use our existing manufacturing footprint that we have around the globe and optimize what products are manufactured in what area around the globe to help optimize some of the supply for our customers.”

“And then in the long-term, we can build our overall manufacturing footprint against the trade environment that ultimately stabilizes,” he continued. “That’s going to be a long-term way in which we help mitigate some of the supply risk, if you will, within our supply chains.”

Intuitive continues global manufacturing expansion

A portrait of Intuitive Surgical CFO Jamie Samath.

Intuitive Surgical CFO Jamie Samath [Photo courtesy of Intuitive Surgical]

Intuitive is expanding its U.S. footprint, Samath said, with two new facilities that opened this year at its Sunnyvale, California headquarters: a 912,000-square-foot facility for da Vinci systems manufacturing and R&D, and a 315,000-square-foot facility for Ion manufacturing and R&D.

The company also recently expanded its Peachtree Corners site in Georgia where the company makes da Vinci X and da Vinci Xi systems.

And before the end of 2025, Intuitive plans to open manufacturing facilities in Germany and Bulgaria while expanding its instrument manufacturing capacity in Mexico, he said.

“In addition to supporting our growth plans, we believe over time these new manufacturing facilities give us supply availability, quality and cost advantages from scale and factory automation,” Samath said.

The company has added about 500 employees so far this year, with about half in manufacturing roles.

“Given long-term opportunities to drive the Quintuple Aim and grow revenue, our resolve to invest in R&D and innovation remain unchanged,” Samath said.

Medtech pay analysis: Intuitive discloses pay for execs and median workers while urging votes against shareholder proposals

Related Articles Read More >

A photo showing the Dualto Energy System's modular design with two generators stacked for two users at a time.
What J&J MedTech’s new Dualto says about the OR of the future — and Ottava
An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's valve being placed in the heart. [Image courtesy of Edwards Lifesciences]
Q&A with Darshin Patel, who led the Edwards Lifesciences Sapien M3 TMVR system’s development
How medical device companies can lead the move from PFAS
An illustration showing the Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement (TMVR) system's dock being placed in the heart. [Image courtesy of Edwards Lifesciences]
The Edwards Lifesciences Sapien M3 transcatheter mitral valve replacement system uses nitinol in a new way
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe